ICG-001

ICG-001 is a **small molecule inhibitor** that selectively blocks the interaction between β-catenin and the coactivator CREB-binding protein (CBP), disrupting TCF/β-catenin-mediated transcription involved in Wnt signaling[1][3][5][7][8]. The compound does not inhibit the binding between β-catenin and p300. Its primary mechanism reduces β-catenin/CBP transcriptional activity, resulting in cell cycle arrest and apoptosis in cancer cells such as colon carcinoma, pancreatic ductal adenocarcinoma, high-grade pediatric glioma, meningioma, triple-negative breast cancer, and endometrial cancer[1][2][3][4][5][6][8]. ICG-001 is being explored preclinically and clinically for various cancer types, as well as fibrotic diseases and experimental cardiac injury, for which it shows efficacy in animal models[7].

Brand names

ICG-001ICG001ICG 001

Other names

ICG-001ICG001ICG 001(6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-8-(naphthalen-1-ylmethyl)-4,7-dioxo-3,6,9,9a-tetrahydro-2H-pyrazino[1,2-a]pyrimidine-1-carboxamide